Neuroprotection by caspase inhibitors

J. S. Braun, E. I. Tuomanen, J. L. Cleveland

Research output: Contribution to journalReview articlepeer-review

18 Citations (Scopus)


In the majority of brain diseases, apoptosis causes or exacerbates neuronal damage. Caspases are the final executioners of the apoptotic cell death programme. This family of proteases is implicated in the pathogenesis of many forms of brain damage, including those induced by ischaemia, inflammation or trauma, as well as those arising in Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis and epilepsy. Collectively, these conditions affect more than 10 m people in the USA alone. Apoptosis can be blocked by agents that inhibit caspase activity; these inhibitors have therapeutic benefit in the treatment of several model systems of brain diseases. In this review we focus on recent advances and summarise current knowledge concerning the use of these cell death inhibitors in neuroprotection.

Original languageEnglish
Pages (from-to)1599-1610
Number of pages12
JournalExpert Opinion on Investigational Drugs
Issue number10
Publication statusPublished - 1999
Externally publishedYes


  • Alzheimer's disease
  • Amyotrophic lateral sclerosis
  • Apoptosis
  • Caspase inhibitors
  • Epilepsy
  • Huntington's disease
  • Ischaemia
  • Meningitis
  • Neuronal damage
  • Neuroprotection
  • Trauma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Neuroprotection by caspase inhibitors'. Together they form a unique fingerprint.

Cite this